Trial Profile

PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon beta-1a (Primary) ; Interferon beta-1a; Interferon beta-1b
Indications Multiple sclerosis
Focus Adverse reactions
Acronyms PLENO
Sponsors Biogen

23 Nov 2020 Status changed from active, no longer recruiting to completed.
02 Dec 2019 Planned End Date changed from 30 Mar 2020 to 30 Sep 2020.
02 Dec 2019 Planned primary completion date changed from 30 Mar 2020 to 30 Sep 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com